{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:53:10Z","timestamp":1790837590990,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Friedreich ataxia (FRDA) is an autosomal recessive neuro- and cardio-degenerative disorder caused by decreased expression of frataxin, a protein that localizes to mitochondria and is critical for iron-sulfur-cluster (ISC) assembly. There are no proven effective treatments for FRDA. We previously screened a random shRNA library and identified a synthetic shRNA (gFA11) that reverses the growth defect of FRDA cells in culture. We now report that gFA11 decreases cytokine secretion in primary FRDA fibroblasts and reverts other changes associated with cell senescence. The gene-expression profile induced by gFA11 is remarkably similar to the gene-expression profile induced by the p38 MAPK inhibitor SB203580. We found that p38 phosphorylation, indicating activation of the p38 pathway, is higher in FRDA cells than in normal control cells, and that siRNA knockdown of frataxin in normal fibroblasts also increases p38 phosphorylation. Treatment of FRDA cells with p38 inhibitors recapitulates the reversal of the slow-growth phenotype induced by clone gFA11. These data highlight the involvement of the p38 MAPK pathway in the pathogenesis of FRDA and the potential use of p38 inhibitors as a treatment for FRDA.<\/jats:p>","DOI":"10.1038\/s41598-018-23168-x","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:59:49Z","timestamp":1522285189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Identification of p38 MAPK as a novel therapeutic target for Friedreich\u2019s ataxia"],"prefix":"10.1038","volume":"8","author":[{"given":"M. Grazia","family":"Cotticelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujuan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Tobias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,22]]},"reference":[{"key":"23168_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/NEN.0b013e31827e5762","volume":"72","author":"AH Koeppen","year":"2013","unstructured":"Koeppen, A. H. & Mazurkiewicz, J. E. Friedreich ataxia: neuropathology revised. J Neuropathol Exp Neurol 72, 78\u201390 (2013).","journal-title":"J Neuropathol Exp Neurol"},{"key":"23168_CR2","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ncl.2013.05.002","volume":"31","author":"A Collins","year":"2013","unstructured":"Collins, A. Clinical neurogenetics: friedreich ataxia. Neurol Clin 31, 1095\u2013120 (2013).","journal-title":"Neurol Clin"},{"key":"23168_CR3","doi-asserted-by":"publisher","first-page":"487534","DOI":"10.1155\/2013\/487534","volume":"2013","author":"CM Gomes","year":"2013","unstructured":"Gomes, C. M. & Santos, R. Neurodegeneration in Friedreich\u2019s ataxia: from defective frataxin to oxidative stress. Oxid Med Cell Longev 2013, 487534 (2013).","journal-title":"Oxid Med Cell Longev"},{"key":"23168_CR4","doi-asserted-by":"publisher","first-page":"e1000812","DOI":"10.1371\/journal.pgen.1000812","volume":"6","author":"AC Haugen","year":"2010","unstructured":"Haugen, A. C. et al. Altered gene expression and DNA damage in peripheral blood cells from Friedreich\u2019s ataxia patients: cellular model of pathology. PLoS Genet 6, e1000812 (2010).","journal-title":"PLoS Genet"},{"key":"23168_CR5","first-page":"124","volume":"8","author":"A Bolinches-Amoros","year":"2014","unstructured":"Bolinches-Amoros, A., Molla, B., Pla-Martin, D., Palau, F. & Gonzalez-Cabo, P. Mitochondrial dysfunction induced by frataxin deficiency is associated with cellular senescence and abnormal calcium metabolism. Front Cell Neurosci 8, 124 (2014).","journal-title":"Front Cell Neurosci"},{"key":"23168_CR6","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1172\/JCI64098","volume":"123","author":"T Tchkonia","year":"2013","unstructured":"Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J. & Kirkland, J. L. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 123, 966\u201372 (2013).","journal-title":"J Clin Invest"},{"key":"23168_CR7","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/emboj.2011.69","volume":"30","author":"A Freund","year":"2011","unstructured":"Freund, A., Patil, C. K. & Campisi, J. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J 30, 1536\u201348 (2011).","journal-title":"EMBO J"},{"key":"23168_CR8","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1177\/1087057115600433","volume":"20","author":"MG Cotticelli","year":"2015","unstructured":"Cotticelli, M. G. et al. Phenotypic Screening for Friedreich Ataxia Using Random shRNA Selection. J Biomol Screen 20, 1084\u201390 (2015).","journal-title":"J Biomol Screen"},{"key":"23168_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/0885-4505(92)90056-5","volume":"48","author":"BH Robinson","year":"1992","unstructured":"Robinson, B. H., Petrova-Benedict, R., Buncic, J. R. & Wallace, D. C. Selective killing of cells with oxidative defects in galactose medium: a screening test for affected patient fibroblasts. Biochemical Medicine & Metabolic Biology 48, 122\u20136 (1992).","journal-title":"Biochemical Medicine & Metabolic Biology"},{"key":"23168_CR10","doi-asserted-by":"publisher","first-page":"e3171","DOI":"10.1371\/journal.pone.0003171","volume":"3","author":"Y Wang","year":"2008","unstructured":"Wang, Y., Wang, Y. E., Cotticelli, M. G. & Wilson, R. B. A random shRNA-encoding library for phenotypic selection and hit-optimization. PLoS ONE 3, e3171 (2008).","journal-title":"PLoS ONE"},{"key":"23168_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.molmed.2009.06.005","volume":"15","author":"LR Coulthard","year":"2009","unstructured":"Coulthard, L. R., White, D. E., Jones, D. L., McDermott, M. F. & Burchill, S. A. p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 15, 369\u201379 (2009).","journal-title":"Trends Mol Med"},{"key":"23168_CR12","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.4049\/jimmunol.168.8.4070","volume":"168","author":"J Branger","year":"2002","unstructured":"Branger, J. et al. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 168, 4070\u20137 (2002).","journal-title":"J Immunol"},{"key":"23168_CR13","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. Multiple signaling pathways regulate contractile activity-mediated PGC-1alpha gene expression and activity in skeletal muscle cells. Physiol Rep 2 (2014).","DOI":"10.14814\/phy2.12008"},{"key":"23168_CR14","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cmet.2016.05.010","volume":"23","author":"CD Wiley","year":"2016","unstructured":"Wiley, C. D. & Campisi, J. From Ancient Pathways to Aging Cells-Connecting Metabolism and Cellular Senescence. Cell Metab 23, 1013\u201321 (2016).","journal-title":"Cell Metab"},{"key":"23168_CR15","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1093\/hmg\/dds095","volume":"21","author":"GR Wagner","year":"2012","unstructured":"Wagner, G. R., Pride, P. M., Babbey, C. M. & Payne, R. M. Friedreich\u2019s ataxia reveals a mechanism for coordinate regulation of oxidative metabolism via feedback inhibition of the SIRT3 deacetylase. Hum Mol Genet 21, 2688\u201397 (2012).","journal-title":"Hum Mol Genet"},{"key":"23168_CR16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/ni1584","volume":"9","author":"P Anderson","year":"2008","unstructured":"Anderson, P. Post-transcriptional control of cytokine production. Nat Immunol 9, 353\u20139 (2008).","journal-title":"Nat Immunol"},{"key":"23168_CR17","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1371\/journal.pbio.0060301","volume":"6","author":"JP Coppe","year":"2008","unstructured":"Coppe, J. P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6, 2853\u201368 (2008).","journal-title":"PLoS Biol"},{"key":"23168_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0014-5793(95)00357-F","volume":"364","author":"A Cuenda","year":"1995","unstructured":"Cuenda, A. et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364, 229\u201333 (1995).","journal-title":"FEBS Lett"},{"key":"23168_CR19","doi-asserted-by":"publisher","first-page":"31856","DOI":"10.1074\/jbc.M114.589093","volume":"289","author":"L Tian","year":"2014","unstructured":"Tian, L. et al. Thep38 pathway regulates oxidative stress tolerance by phosphorylation of mitochondrial protein IscU. J Biol Chem 289, 31856\u201365 (2014).","journal-title":"J Biol Chem"},{"key":"23168_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1042\/BJ20111637","volume":"441","author":"H Yoon","year":"2012","unstructured":"Yoon, H. et al. Mutation in the Fe-S scaffold protein Isu bypasses frataxin deletion. Biochem J 441, 473\u201380 (2012).","journal-title":"Biochem J"},{"key":"23168_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1042\/BJ20131273","volume":"459","author":"H Yoon","year":"2014","unstructured":"Yoon, H. et al. Frataxin-bypassing Isu1: characterization of the bypass activity in cells and mitochondria. Biochem J 459, 71\u201381 (2014).","journal-title":"Biochem J"},{"key":"23168_CR22","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/1531-8249(199905)45:5<673::AID-ANA20>3.0.CO;2-Q","volume":"45","author":"MB Delatycki","year":"1999","unstructured":"Delatycki, M. B. et al. Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann. Neurol. 45, 673\u2013675 (1999).","journal-title":"Ann. Neurol."},{"key":"23168_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/1087057111427949","volume":"17","author":"MG Cotticelli","year":"2012","unstructured":"Cotticelli, M. G. et al. Primary and secondary drug screening assays for Friedreich ataxia. J Biomol Screen 17, 303\u201313 (2012).","journal-title":"J Biomol Screen"},{"key":"23168_CR24","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.redox.2013.06.004","volume":"1","author":"MG Cotticelli","year":"2013","unstructured":"Cotticelli, M. G., Crabbe, A. M., Wilson, R. B. & Shchepinov, M. S. Insights into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids. Redox Biol 1, 398\u2013404 (2013).","journal-title":"Redox Biol"},{"key":"23168_CR25","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1073\/pnas.091062498","volume":"98","author":"VG Tusher","year":"2001","unstructured":"Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98, 5116\u201321 (2001).","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23168-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23168-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23168-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T03:44:43Z","timestamp":1671594283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23168-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,22]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["23168"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-23168-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,22]]},"assertion":[{"value":"27 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Robert B. Wilson and Yongping Wang have patents, in conjunction with the University of Pennsylvania, related to the construction and methods of use of random shRNA-expressing libraries. M. Grazia Cotticelli, Shujuan Xia, Avinash Kaur, Yongping Wang, John W. Tobias, and Robert B. Wilson have a provisional patent application, in conjunction with the University of Pennsylvania, on the use of p38 inhibitors for the treatment of FRDA; this provisional patent was licensed to FA Therapeutics LLC, in which Robert B. Wilson has a 5% equity interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5007"}}